



## Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

September 2, 2021

SAN DIEGO, Sept. 2, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following virtual investor conferences:



- Kevin Gorman, Chief Executive Officer, will present at the Morgan Stanley 19<sup>th</sup> Annual Healthcare Conference at 10:15 a.m. ET on Monday, Sept. 13, 2021.
- Matt Abernethy, Chief Financial Officer, and Eiry Roberts, Chief Medical Officer, will present at the Baird 2021 Global Healthcare Conference at 10:50 a.m. ET on Wednesday, Sept. 15, 2021.

The live presentation will be webcast and may be accessed on the Company's website under Investors at [www.neurocrine.com](http://www.neurocrine.com). A replay of the presentation will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.

### About Neurocrine Biosciences

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis\*, uterine fibroids\* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit [neurocrine.com](http://neurocrine.com), and follow the company on [LinkedIn](#). (\*in collaboration with AbbVie)

View original content to download multimedia: <https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-upcoming-healthcare-conferences-301368799.html>

SOURCE Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc., Tony Jewell (Media), 858-617-7578, [media@neurocrine.com](mailto:media@neurocrine.com), or Todd Tushla (Investors), 858-617-7143, [ir@neurocrine.com](mailto:ir@neurocrine.com)